DEP® presentation at SNMMI radiopharmaceuticals conference (ASX Announcement)
Jun 12th, 2024
Starpharma (ASX: SPL, OTCQX: SPHRY) today provides a copy of the DEP® radiotheranostics scientific poster presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Toronto, Canada, overnight. The scientific poster presents data from Starpharma’s DEP® HER2 radiotheranostics program, demonstrating the promising utility of DEP® dendrimers in precision radiotheranostics for cancer imaging and therapeutic applications.
Read More
DEP® irinotecan presentation at ASCO 2024 Annual Meeting (ASX Announcement)
Jun 4th, 2024
Starpharma (ASX: SPL, OTCQX: SPHRY) today provides a copy of the DEP® irinotecan presentation delivered at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, US. The presentation was part of a rapid oral abstract session and highlighted the final results of the DEP® irinotecan Phase 1/2 clinical trial, which were reported in full last week.
Read More
DEP® cabazitaxel presentation at ASCO 2024 Annual Meeting (ASX Announcement)
Jun 3rd, 2024
Starpharma (ASX: SPL, OTCQX: SPHRY) today provides a copy of the DEP® cabazitaxel presentation that was delivered at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, US. The presentation was part of an oral abstract session showcasing the final results of the DEP® cabazitaxel Phase 1/2 clinical trial.
Read More
Starpharma announces positive final DEP® irinotecan Phase 2 clinical trial results (ASX Announcement)
May 27th, 2024
Starpharma announces the full results of the Phase 2 open-label clinical trial of DEP® irinotecan. The trial met its objectives, with endpoints demonstrating positive anti-tumour efficacy of DEP® irinotecan in heavily pre-treated patients with a range of difficult-to-treat, advanced, metastatic cancers, including colorectal cancer (CRC) and platinum-resistant ovarian cancer.
Read More
Investor Webinar - Starpharma Business Update (22 May 2024)
May 24th, 2024
Starpharma hosted an investor webinar on Wednesday, 22 May 2024, to provide shareholders with a business update.
Starpharma’s CEO, Cheryl Maley, hosted the webinar, alongside the CFO and Company Secretary, Justin Cahill, VP of Business Development, Dr Tony Eglezos, and VP of Development and Regulatory Affairs, Dr Jeremy Paull.
Read More
Ex-Novartis boss shines as CEO
May 23rd, 2024
"In less than five months at the helm of Starpharma, Cheryl Maley, has established a pathway to increase the company's revenue by "accelerating commercial opportunities" and "building stronger brands" for its existing products".
Read More
Starpharma Business Update (ASX Announcement)
May 22nd, 2024
Starpharma dedicated to helping patients with significant illness, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology, is pleased to provide shareholders with a business update following an extensive review of strategy and operations, led by Starpharma’s CEO, Cheryl Maley, alongside the leadership team and Board of Directors.
Read More
Investor Webinar Notification – Starpharma Business Update (ASX Announcement)
May 20th, 2024
Starpharma (ASX: SPL, OTCQX: SPHRY) is pleased to announce that it will host an investor webinar on Wednesday, 22 May 2024, to provide shareholders with a business update.
Read More
Quarterly Activities Report & Appendix 4C (ASX Announcement)
Apr 30th, 2024
Starpharma (ASX: SPL, OTCQX: SPHRY), which is dedicated to enhancing the quality of life for patients with unmet medical needs, such as cancer, by creating innovative therapies using dendrimer technology, today releases its Quarterly Activities Report and Appendix 4C for the period ended 31 March 2024 (Q3 FY24). Starpharma’s closing cash balance as at 31 March 2024 was $26.6 million.
Read More
Which ASX companies are resurrecting abandoned drugs? Part 3
Apr 18th, 2024
"SPL has developed its proprietary Dendrimer Enhanced Products platform (DEP) to improve the effectiveness and safety of drugs, especially cancer treatments." Read the full article in Stockhead.
Read More
Which ASX companies are resurrecting abandoned drugs? Part 3
Apr 18th, 2024
DEP is based on dendrimers, which are highly branched polymers, to enhance the delivery of cancer treatments and reduce toxic side effects such as neutropenia, nausea, severe diarrhoea and hair loss from chemotherapy agents. Read the full article in The Australian Business Review.
Read More
Investor Webinar - Starpharma and Medicxi Partnership: Petalion Therapeutics (9 April 2024)
Apr 10th, 2024
Starpharma hosted an investor webinar on Tuesday, 9 April 2024. The session focused on the ASX Announcement lodged on 8 April 2024, 'Starpharma and Medicxi Partnership Petalion Therapeutics', about the strategic partnership with Medicxi and the formation of a new company called Petalion Therapeutics.
Read More
Breaking new ground via an oncology treatment tech venture
Apr 9th, 2024
Cheryl Maley, CEO of Starpharma (SPL), provides insight into the partnreship with Medicxi, materialising in Petalion Therapeutics in the UK.
Read More
Aussie tech behind new company
Apr 9th, 2024
Starpharma's partnership with Medicxi was featured in Pharma In Focus.
Read More
Australia's Starpharma and UK-based Medicxi create Petalion Therapeutics to develop novel dendrimer-based treatments
Apr 9th, 2024
Read the coverage of Starpharma's partnership with Medicxi in BioSpectrum Asia.
Read More
Starpharma and Medicxi to partner in Petalion Therapeutics, advancing dendrimer-drug cancer treatments
Apr 9th, 2024
"Australian biotech Starpharma Holdings (ASX: SPL) has entered into a strategic partnership with UK life sciences investment firm Medicxi to establish a UK-based company known as Petalion Therapeutics."
Read More
Investor Webinar Notification – Starpharma x Medicxi Partnership (ASX Announcement)
Apr 8th, 2024
Starpharma (ASX: SPL, OTCQX: SPHRY) is pleased to announce that it will host an investor webinar on Tuesday, 9 April 2024.
Read More
Medicxi and Starpharma create Petalion Therapeutics to develop novel dendrimer-based treatments (ASX Announcement)
Apr 8th, 2024
Medicxi to invest up to USD $25M into newly established entity, Petalion Therapeutics, led by highly experienced pharmaceutical executive Dr Mehdi Shahidi
Read More
Half Yearly Report and Accounts (ASX Announcement)
Feb 28th, 2024
Starpharma (ASX: SPL, OTCQX: SPHRY) today releases its Interim Report and Half-Year Financial Results for the period ended 31 December 2023 (H1 FY24).
Read More
VivaGel® BV US FDA Appeal Outcome (ASX Announcement)
Feb 19th, 2024
Starpharma (ASX: SPL, OTCQX: SPHRY) today announces that it has completed the formal dispute resolution process with the US Food and Drug Administration (FDA) in relation to VivaGel® BV. The FDA has maintained its position that they require additional clinical efficacy data to be generated for the regulatory approval of VivaGel® BV for bacterial vaginosis (BV) in the US. The formal dispute resolution process involved multiple submissions, meetings, detailed analyses, and the preparation of regulatory precedents relating to recent product approvals. Starpharma was supported through this process by highly experienced regulatory advisers, key opinion leaders, and biostatistical and legal advisers, including several who were ex-FDA.
Read More
Quarterly Activities Report & Appendix 4C (ASX Announcement)
Jan 31st, 2024
Starpharma (ASX: SPL, OTCQX: SPHRY) today releases its Quarterly Activities Report and Appendix 4C for the period ended 31 December 2023 (Q2 FY24). Starpharma’s closing cash balance as at 31 December 2023 was $32.1 million.
Read More
Viraleze shows antiviral efficacy in COVID-19 patients (ASX Announcement)
Jan 29th, 2024
Starpharma (ASX: SPL, OTCQX: SPHRY) today announces the results of the post-market clinical study of Viraleze™ nasal spray in participants with COVID-19, demonstrating that Viraleze™ reduced SARS-CoV-2 viral load in the nose, increased the rate of virus clearance from the nose, improved key symptoms of COVID-19, including loss of smell (anosmia), and was well-tolerated.
Read More
VivaGel® BV sales and distribution agreement – MENA region (ASX Announcement)
Jan 22nd, 2024
Starpharma (ASX: SPL, OTCQX: SPHRY) today announces it has signed a sales and distribution agreement for its VivaGel® BV product with ITROM Pharmaceutical Group, covering 13 countries across the Middle East and North Africa (MENA) region. In this region, the prevalence of bacterial vaginosis among a female population of 238 million is 25%, indicating a high need for new effective therapeutic approaches and a significant opportunity for VivaGel® BV.
Read More
DEP® cabazitaxel data presentation at ASCO GI cancer meeting (ASX Announcement)
Jan 19th, 2024
Starpharma (ASX: SPL, OTCQX: SPHRY) today announces the presentation of the positive results from its Phase 2 clinical trial of DEP® cabazitaxel at the American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, which is being held from 18 to 20 January 2024 in San Francisco, US. ASCO is the world's leading professional organisation for physicians and oncology professionals. The ASCO GI Cancers Symposium is the only global meeting of its kind focusing on the latest innovative science and clinical developments in GI cancer treatment, research, and care. It brings together oncology thought leaders, practising clinicians, novel drug developers, and GI specialists from around the world.
Read More
Positive DEP® docetaxel Phase 2 results (ASX Announcement)
Dec 19th, 2023
Starpharma today announces positive final results from the completed Phase 2 clinical program of DEP® docetaxel. The clinical program included a monotherapy arm and two combination arms. The Phase 2 trial objectives were met, with endpoints demonstrating encouraging anti-tumour activity of DEP® docetaxel when administered as a monotherapy or in combination with other anti-cancer agents, nintedanib or gemcitabine, in multiple advanced, metastatic cancers, including pancreatic, gastro-oesophageal, non-small cell lung cancer (NSCLC) and cholangiocarcinoma.
Read More
Starpharma to present DEP® at Radiopharmaceuticals Summit (ASX Announcement)
Dec 6th, 2023
Starpharma (ASX: SPL, OTCQX: SPHRY) today announces it is presenting at the Targeted Radiopharmaceuticals Summit Europe, having been invited to present at the specialist radiotheranostics conference being held in Berlin, Germany, from 5 to 7 December 2023.
Read More
Results of 2023 Annual General Meeting (ASX Announcement)
Nov 30th, 2023
Melbourne, Australia; 29 November 2023: Starpharma (ASX: SPL, OTCQX: SPHRY) announces the details of the resolutions and the proxies and votes received in respect of each resolution at its Annual General Meeting (AGM) held today in accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act, as set out in the attached proxy and voting summary. ... View/download... Read More
AGM Chairman's address and CEO's presentation (ASX Announcement)
Nov 30th, 2023
Starpharma (ASX: SPL, OTCQX: SPHRY) releases the attached Chairman’s address and the CEO’s presentation to the Annual General Meeting (AGM) of Starpharma Holdings Limited, to be held today at 2:00 pm (Melbourne time).
Read More
Notice of Annual General Meeting 2023 - Clarification (ASX Announcement)
Nov 15th, 2023
Starpharma refers to its Notice of Annual General Meeting dated 27 October 2023 (Notice).
Read More
Starpharma to present at Bell Potter Healthcare Conference (ASX Announcement)
Nov 14th, 2023
Starpharma has been invited to present today at the Bell Potter Healthcare Conference, a virtual investor conference that showcases Australia's leading healthcare companies to institutional investors and Bell Potter’s retail network.
Read More
Starpharma announces new CEO, Ms Cheryl Maley (ASX Announcement)
Nov 10th, 2023
Starpharma is today pleased to announce the appointment of Ms Cheryl Maley as Chief Executive Officer (CEO) and Managing Director of Starpharma effective 8 January 2024.
Read More
Quarterly Activities Report & Appendix 4C (ASX Announcement)
Oct 31st, 2023
Starpharma today releases its Quarterly Activities Report and Appendix 4C for the period ended 30 September 2023 (Q1 FY24).
Read More
SPL to present DEP radiotheranostics at Wilsons Conference (ASX Announcement)
Oct 26th, 2023
Starpharma today announces that it will present at the Wilsons Drug and Device Conference tomorrow, 27 October 2023, at 10:00 AM AEST.
Read More
Starpharma receives $7.2 million R&D Tax Incentive refund (ASX Announcement)
Oct 23rd, 2023
Starpharma today announces it has received a $7.2 million research and development (R&D) tax incentive refund under the Australian Federal Government’s R&D Tax Incentive scheme.
Read More
Positive DEP® Cabazitaxel Phase 2 Results in Multiple Cancers (ASX Announcement)
Oct 18th, 2023
Starpharma today announces the final positive results from its completed Phase 2 open-label clinical trial of DEP® cabazitaxel. The trial met its objectives, with endpoints demonstrating positive anti-tumour efficacy of DEP® cabazitaxel in advanced, metastatic castrate-resistant prostate cancer (mCRPC), as well as other difficult-to-treat cancers, including platinum-resistant ovarian cancer and gastro-oesophageal cancers.
Read More
DEP® irinotecan IO/PARP combination data presented at AACR (ASX Announcement)
Oct 16th, 2023
Starpharma (ASX: SPL, OTCQX: SPHRY) today provides a copy of the DEP® irinotecan combination data poster, showcasing the recently announced1 data for DEP® irinotecan in combination with leading anticancer therapies, including immuno-oncology (IO) agents, in human colorectal cancer (CRC) models.
Read More
DEP® irinotecan clinical data presented at AACR meeting (ASX Announcement)
Oct 16th, 2023
Starpharma today provides a copy of the DEP® irinotecan clinical poster, highlighting the recently announced1 positive interim clinical data from Starpharma’s Phase 1/2 clinical trial, which demonstrated durable anti-tumour responses in advanced colorectal cancer (CRC) and platinum-resistant/refractory ovarian cancer.
Read More
DEP® theranostic presented at international oncology meeting (ASX Announcement)
Oct 16th, 2023
Starpharma today provides a copy of the poster that showcases the results from a study of DEP® HER2-zirconium, Starpharma’s HER2-targeted radiodiagnostic candidate, which demonstrated a favourable biodistribution profile, with excellent imaging contrast between tumour and normal tissues, as well as rapid uptake and high levels of tumour accumulation in a HER2+ breast cancer model.
Read More
Date of Starpharma’s Annual General Meeting 2023 (ASX Announcement)
Oct 2nd, 2023
Starpharma today announces, in accordance with ASX Listing Rule 3.13.1, that its 2023 Annual General Meeting (AGM) will be held at 2:00 p.m. (Melbourne time) on Wednesday, 29 November 2023.
Read More
DEP® irinotecan combination data to be presented at international oncology conference (ASX Announcement)
Sep 27th, 2023
Starpharma today announces the presentation of data that demonstrate the benefits of combining DEP® irinotecan with other important classes of anti-cancer therapies, including immuno-oncology (IO) agents, in models of human colorectal cancer.
Read More
VIRALEZE™ UK COVID-19 Clinical Study Completes Recruitment (ASX Announcement)
Sep 25th, 2023
Starpharma (ASX: SPL, OTCQX: SPHRY) today announces that it has completed recruitment for the post-market clinical study of its broad-spectrum antiviral barrier nasal spray, VIRALEZE™, in patients with COVID-19 in the UK. Recruitment proceeded rapidly and the study successfully enrolled ~200 patients with laboratory-confirmed COVID-19.
Read More
Starpharma featured on Bulls N' Bears
Sep 22nd, 2023
Starpharma was featured on 3AW's Bulls N' Bears following the announcement about positive DEP® irinotecan clinical results that will be presented at international oncology conference. This was recorded on 20 September 2023. ... Read More
Starpharma featured on ShareCafe
Sep 22nd, 2023
Starpharma was featured on ShareCafe's "Hidden Gems Webinar" following the announcement about positive DEP® irinotecan clinical results that will be presented at international oncology conference. This was recorded on 22 September 2023. ... ... Read More
Starpharma interviewed for Fear and Greed podcast
Sep 22nd, 2023
Starpharma was featured in Business News' Fear and Greed following the announcement about positive DEP® irinotecan clinical results that will be presented at international oncology conference.This was recorded on 20 September 2023. ... Read More
Starpharma interviewed for ausbiz
Sep 15th, 2023
Starpharma was featured in ausbiz's Small Caps segment following the announcement about positive DEP® irinotecan clinical results that will be presented at international oncology conference.This was recorded on 14 September 2023. Read More
Positive DEP® irinotecan clinical results to be presented at international oncology conference (ASX Announcement)
Sep 13th, 2023
Starpharma today announces positive interim results from its Phase 1/2 clinical trial of DEP® irinotecan will be presented at the upcoming American Association of Cancer Research (AACR), National Cancer Institute (NCI) and European Organisation for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics in Boston, US, from 11 to 15 October 2023.
Read More
Change of Company Secretary (ASX Announcement)
Aug 28th, 2023
Starpharma today announces, in accordance with ASX Listing Rule 3.16.1, that Tracy Weimar has resigned as Company Secretary, a role that was conducted for an interim period.
Read More
Appendix 4G – Corporate Governance Statement (ASX Announcement)
Aug 24th, 2023
Starpharma today releases its Appendix 4G – Key to Disclosures Corporate Governance Council Principles and Recommendations, in accordance with ASX Listing Rules 4.7.3 and 4.10.3.
Read More
Starpharma annual report and full-year financial results (ASX Announcement)
Aug 24th, 2023
Starpharma today releases its annual report and full-year financial results for the year ended 30 June 2023.
Read More
Starpharma to receive A$6.5M from Mundipharma and rights to VivaGel® BV (ASX Announcement)
Aug 14th, 2023
Starpharma today announces it has negotiated a commercial settlement agreement with Mundipharma in relation to the VivaGel® BV product.
Read More